NCT00085293View on ClinicalTrials.gov

Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

January 31, 2014

Study Completion Date

May 31, 2014

Conditions
Recurrent Thyroid CancerStage IVA Follicular Thyroid CancerStage IVA Papillary Thyroid CancerStage IVB Follicular Thyroid CancerStage IVB Papillary Thyroid CancerStage IVC Follicular Thyroid CancerStage IVC Papillary Thyroid Cancer
Interventions
DRUG

Decitabine

Starting dose 6 mg/m\^2 intravenously over 1 hour every day for 5 successive days for 2 weeks (10 doses), with possible second course.

RADIATION

Iodine I 131

Undergo thyrotropin-alfa stimulated radioactive iodine scan

BIOLOGICAL

Recombinant thyrotropin alfa

Undergo thyrotropin-alfa stimulated radioactive iodine scan

RADIATION

Fludeoxyglucose F 18

Optional correlative studies

PROCEDURE

Positron emission tomography

Optional correlative studies

Trial Locations (3)

43210

Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus

77030

M D Anderson Cancer Center, Houston

80045

University of Colorado at Denver, Aurora

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00085293 - Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131 | Biotech Hunter | Biotech Hunter